Co-Diagnostics Inc (NASDAQ:CODX)’s share price traded up 5.5% during trading on Monday . The company traded as high as $1.24 and last traded at $1.16, 296,483 shares were traded during trading. A decline of 68% from the average session volume of 914,189 shares. The stock had previously closed at $1.10.

A number of equities analysts have commented on the company. Maxim Group set a $2.00 price objective on Co-Diagnostics and gave the stock a “buy” rating in a research note on Thursday, July 11th. Zacks Investment Research lowered Co-Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, July 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Co-Diagnostics in a research note on Friday.

The company has a 50 day moving average price of $1.12 and a 200-day moving average price of $1.06.

Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). Co-Diagnostics had a negative net margin of 7,369.12% and a negative return on equity of 267.08%. The business had revenue of $0.06 million during the quarter. On average, equities analysts expect that Co-Diagnostics Inc will post -0.09 earnings per share for the current year.

An institutional investor recently raised its position in Co-Diagnostics stock. Vanguard Group Inc. grew its holdings in Co-Diagnostics Inc (NASDAQ:CODX) by 142.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 340,175 shares of the company’s stock after purchasing an additional 199,685 shares during the period. Vanguard Group Inc. owned approximately 2.00% of Co-Diagnostics worth $281,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 10.61% of the company’s stock.

Co-Diagnostics Company Profile (NASDAQ:CODX)

Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc was founded in 2013 and is headquartered in Salt Lake City, Utah.

Further Reading: What is quantitative easing?

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.